Biogen is heading into one of the most significant weeks in its recent history — and Truist Securities just stepped in with a timely upgrade. The investment bank lifted Biogen to buy from hold on Monday, raising its 12-month price target to $235 from $190. That implies roughly 18% upside from Friday’s close. The catalyst: new Phase 2 data from Biogen’s investigational Alzheimer’s drug is set to drop on Tuesday, July 14, at the Alzheimer’s Association International Conference (AAIC) in London. If the data is strong, the stock could move significantly. And the signals heading in are unusually positive.
The drug in question is Diranersen (BIIB080), an antisense oligonucleotide therapy targeting tau protein — one of the key biological drivers of Alzheimer’s disease. Tau tangles accumulate in the brain as the disease progresses, and blocking that process is considered one of the most promising but difficult frontiers in neuroscience. Truist analyst Danielle Brill said management’s tone ahead of the conference read “very positive,” and added that the fact Biogen is already planning a Phase 3 trial signals the Phase 2 evidence was compelling. “While specific details were not shared due to AAIC’s strict embargo policy, the fact that BIIB is planning a Phase 3 trial signals to us that the evidence was compelling,” Brill wrote. The bar was set high, and Biogen appears to have cleared it. Beyond the Alzheimer’s data, Truist also highlighted Felzartamab, Biogen’s investigational kidney disease treatment, with key Phase 3 data expected in mid-2027. The pipeline is broader than the market currently values.
For retail investors, the setup here is a classic pre-catalyst play with an unusually clear timeline. The data drops Tuesday. If Phase 2 results show meaningful tau reduction and a clean safety profile, the market’s response could be swift — 23 of 38 Wall Street analysts covering Biogen already have a buy or strong buy rating on the stock. The risk is binary, as it always is with clinical trial data: a miss or mixed results could weigh on shares. But with Truist upgrading ahead of the release and management signaling confidence, the risk/reward leans constructive for investors with a 12-month time horizon. Biogen has been one of biotech’s more frustrating underperformers in recent years. Tomorrow’s data readout could be the inflection point that changes that narrative.
